Abstract
Mineralocorticoid receptor blockade is useful in patients with heart failure and chronic kidney disease. However, according to these guidelines, along with {1}, the risk of side effects, such as hyperkalemia and renal dysfunction, makes eplerenone and spironolactone the least frequently prescribed medications among all those recommended for the treatment of heart failure. This means that there is a clear need for new mineralocorticoid receptor antagonists that have greater effects on the heart than on the kidney. This Recommendation is of an article referenced in an F1000Prime Report also written by Anne Dorrance.